{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,7,10]],"date-time":"2024-07-10T11:09:21Z","timestamp":1720609761763},"reference-count":24,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2008,6,1]],"date-time":"2008-06-01T00:00:00Z","timestamp":1212278400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Enfermedades Infecciosas y Microbiolog\u00eda Cl\u00ednica"],"published-print":{"date-parts":[[2008,6]]},"DOI":"10.1157\/13126268","type":"journal-article","created":{"date-parts":[[2008,11,22]],"date-time":"2008-11-22T18:15:16Z","timestamp":1227377716000},"page":"19-24","source":"Crossref","is-referenced-by-count":1,"special_numbering":"S8","title":["Tenofovir como estrategia para evitar o detener efectos adversos"],"prefix":"10.1016","volume":"26","author":[{"given":"Joaqu\u00edn","family":"Portilla","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1157\/13126268_bib1","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1016\/S0140-6736(99)06102-4","article-title":"Mitochondrial toxicity induced by nucleoside-analogue reverse-transcriptase inhibitors is a key factor in the pathogenesis of antiretroviral-therapy-related lipodystrophy","volume":"354","author":"Brinkman","year":"1999","journal-title":"Lancet"},{"key":"10.1157\/13126268_bib2","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1177\/135965350400900317","article-title":"Prevalence of lipoatrophy and mitochondrial DNA content of blood and subcutaneous fat in HIV-1-infected patients randomly allocated to zidovudine- or stavudine-based therapy","volume":"9","author":"Van der Valk","year":"2004","journal-title":"Antiviral Ther"},{"key":"10.1157\/13126268_bib3","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1016\/S0140-6736(00)04056-3","article-title":"Risk of lipodystrophy in HIV-1-infected patients treated with protease inhibitors: a prospective cohort study","volume":"357","author":"Mart\u00ednez","year":"2001","journal-title":"Lancet"},{"key":"10.1157\/13126268_bib4","doi-asserted-by":"crossref","first-page":"2493","DOI":"10.1097\/00002030-199912240-00002","article-title":"Fat distribution and metabolic changes in patients with HIV infection","volume":"13","author":"Safrin","year":"1999","journal-title":"AIDS"},{"key":"10.1157\/13126268_bib5","series-title":"14th Conference on retrovirus and opportunistic infections","article-title":"Metabolic outcomes of ACTG 5142: A prospective, randomized, phase III trial of NRTI-, PI-, and NNRTI-sparing regimens for initial treatment of HIV-1 infection","author":"Haubrich","year":"2007"},{"key":"10.1157\/13126268_bib6","series-title":"14th Conference on retrovirus and opportunistic infections, Los Angeles","article-title":"Significant sparing of peripheral lipoatrophy by HIV treatment with LPV\/r + ZDV\/3TC induction followed by LPV\/r monotheraphy compared with EFV + ZDV\/3TC","author":"Cameron","year":"2007"},{"key":"10.1157\/13126268_bib7","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1001\/jama.292.2.191","article-title":"Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial","volume":"292","author":"Gallant","year":"2004","journal-title":"JAMA"},{"key":"10.1157\/13126268_bib8","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1056\/NEJMoa051871","article-title":"Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV","volume":"354","author":"Gallant","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1157\/13126268_bib9","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1056\/NEJMoa012035","article-title":"Changes in mitochondrial DNA as a marker of nucleoside toxicity in HIV-infected patients","volume":"346","author":"Cote","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1157\/13126268_bib10","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1128\/AAC.46.3.716-723.2002","article-title":"Assessment of mitochondrial toxicity in human cells treated with tenofovir: comparison with other nucleoside reverse transcriptase inhibitors","volume":"46","author":"Birkus","year":"2002","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1157\/13126268_bib11","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1001\/jama.292.2.191","article-title":"Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial","volume":"292","author":"Gallant","year":"2004","journal-title":"JAMA"},{"key":"10.1157\/13126268_bib12","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1056\/NEJMoa051871","article-title":"Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV","volume":"354","author":"Gallant","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1157\/13126268_bib13","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1097\/QAI.0b013e31815acab8","article-title":"Tenofovir disoproxil fumarate, emtricitabine, and efavirenz compared with zidovudine\/lamivudine and efavirenz in treatment-naive patients: 144-week","volume":"47","author":"Arribas","year":"2008","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1157\/13126268_bib14","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1056\/NEJMoa062744","article-title":"Class of antiretroviral drugs and the risk of myocardial infarction","volume":"356","author":"Friis-Moller","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1157\/13126268_bib15","doi-asserted-by":"crossref","first-page":"2043","DOI":"10.1097\/01.aids.0000247574.33998.03","article-title":"A randomized comparative trial of tenofovir DF or abacavir as replacement for a thymidine analogue in persons with lipoatrophy","volume":"20","author":"Moyle","year":"2006","journal-title":"AIDS"},{"key":"10.1157\/13126268_bib16","series-title":"Program and abstracts of the 12th Conference on Retroviruses and Opportunistic Infections","article-title":"Improvement of subcutaneous fat, lipid profile, and parameters of mitochondrial toxicity in patients with peripheral lipoatrophy when stavudine is switched to tenofovir: the LIPOTEST study","author":"Ribera","year":"2005"},{"key":"10.1157\/13126268_bib17","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1310\/hct0806-381","article-title":"The safety and efficacy of switching stavudine to tenofovir df in combination with lamivudine and efavirenz in hiv-1-infected patients: three-year follow-up after switching therapy","volume":"8","author":"Valdez","year":"2007","journal-title":"HIV Clin Trials"},{"key":"10.1157\/13126268_bib18","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1097\/01.aids.0000233574.49220.de","article-title":"Sustained improvement of dyslipidaemia in HAART-treated patients replacing stavudine with tenofovir","volume":"20","author":"Llibre","year":"2006","journal-title":"AIDS"},{"key":"10.1157\/13126268_bib19","series-title":"4th IAS Conference on HIV Pathogenesis, Treatment and Prevention. Sydney","article-title":"A randomized comparison of the safety of continued zidovudine plus lamivudine (Combivir, CBV) versus switching to tenofovir DF plus emtricitabine (Truvada, TVD) each plus efavirenz (EFV) in stable HIV-infected persons: results of a planned 24-week analysis","author":"Moyle","year":"2007"},{"key":"10.1157\/13126268_bib20","series-title":"4th IAS Conference on HIV Pathogenesis, Treatment and Prevention","article-title":"Efficacy and safety of NRTI's switch to tenofovir plus emtricitabine (Truvada) vs. abacavir plus lamivudine (Kivexa) in patients with virologic suppression receiving a lamivudine containing HAART: The BICOMBO study","author":"Mart\u00ednez","year":"2007"},{"key":"10.1157\/13126268_bib21","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1097\/01.qai.0000143599.64234.15","article-title":"Body composition and metabolic changes in antiretroviral-naive patients randomized to didanosine and stavudine vs. abacavir and lamivudine","volume":"38","author":"Shlay","year":"2005","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1157\/13126268_bib22","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1097\/QAD.0b013e3282f33557","article-title":"Zidovudine\/lamivudine contributes to insulin resistance within 3 months of starting combination antiretroviral therapy","volume":"22","author":"Bl\u00fcmer","year":"2008","journal-title":"AIDS"},{"key":"10.1157\/13126268_bib23","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1097\/QAD.0b013e32827038d0","article-title":"Antiretroviral therapy exposure and incidence of diabetes mellitus in the Wome\u0144s Interagency HIV Study","volume":"21","author":"Tien","year":"2007","journal-title":"AIDS"},{"key":"10.1157\/13126268_bib24","series-title":"Program and abstracts of the 15th Annual Canadian Conference on HIV\/AIDS Research","article-title":"Effects of switching from fixed dose zidovudine\/lamivudine (CBV) to fixed dose tenofovir DF\/emtricitabine (TVD): maintenance of virologic suppression and other benefits","author":"DeJes\u00fas","year":"2006"}],"container-title":["Enfermedades Infecciosas y Microbiolog\u00eda Cl\u00ednica"],"original-title":[],"language":"es","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0213005X08765273?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0213005X08765273?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,5,21]],"date-time":"2023-05-21T08:11:53Z","timestamp":1684656713000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0213005X08765273"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,6]]},"references-count":24,"alternative-id":["S0213005X08765273"],"URL":"https:\/\/doi.org\/10.1157\/13126268","relation":{},"ISSN":["0213-005X"],"issn-type":[{"value":"0213-005X","type":"print"}],"subject":[],"published":{"date-parts":[[2008,6]]}}}